Bradley J Monk Selected Research

Platinum

12/2022	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
10/2022	Survival with Cemiplimab in Recurrent Cervical Cancer.
1/2022	Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
1/2022	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
1/2022	Clear cell carcinoma of the endometrium.
12/2021	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
11/2021	Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
11/2021	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
11/2021	Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
9/2021	RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bradley J Monk Research Topics

Disease

97	Neoplasms (Cancer) 01/2022 - 03/2002
90	Ovarian Neoplasms (Ovarian Cancer) 12/2022 - 10/2002
68	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2022 - 12/2002
43	Carcinoma (Carcinomatosis) 01/2022 - 11/2002
25	Disease Progression 10/2022 - 07/2004
22	Ovarian Epithelial Carcinoma 07/2022 - 03/2005
14	Neutropenia 12/2022 - 01/2009
11	Hypertension (High Blood Pressure) 01/2017 - 01/2005
7	Anemia 12/2022 - 03/2009
6	Neoplasm Metastasis (Metastasis) 11/2021 - 09/2003
5	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 07/2009
5	Adenocarcinoma 01/2021 - 12/2007
5	Ascites 01/2017 - 03/2010
5	Pain (Aches) 05/2012 - 07/2005
5	Uterine Cervical Dysplasia 01/2007 - 01/2002
4	Fallopian Tube Neoplasms 01/2022 - 01/2019
4	Fatigue 01/2021 - 01/2005
4	Body Weight (Weight, Body) 10/2020 - 12/2011
4	Thrombocytopenia (Thrombopenia) 01/2019 - 01/2012
4	Leiomyosarcoma 12/2018 - 09/2006
3	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 01/2012
3	Nausea 11/2020 - 01/2011
3	Fistula 10/2017 - 03/2009
3	Hemorrhage 10/2017 - 07/2014
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2009 - 08/2004
2	Neoplasm Micrometastasis 11/2021 - 01/2016
2	Vomiting 11/2020 - 01/2017
2	Adenosquamous Carcinoma 01/2020 - 01/2009
2	Infections 01/2019 - 11/2014
2	Carcinogenesis 01/2019 - 08/2012
2	Thromboembolism 10/2017 - 11/2007
2	Necrosis 01/2017 - 01/2016
2	Breast Neoplasms (Breast Cancer) 11/2016 - 01/2010
2	Endometrioid Carcinoma 01/2016 - 09/2015
2	Diarrhea 10/2014 - 08/2010

Drug/Important Bio-Agent (IBA)

49	PlatinumIBA 12/2022 - 11/2004
38	Bevacizumab (Avastin)FDA Link 11/2021 - 03/2005
29	Paclitaxel (Taxol)FDA LinkGeneric 11/2021 - 09/2005
26	Cisplatin (Platino)FDA LinkGeneric 10/2017 - 08/2004
18	Pharmaceutical PreparationsIBA 11/2021 - 01/2005
16	liposomal doxorubicin (Doxil)FDA Link 11/2021 - 01/2005
16	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 12/2009
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2004
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020 - 03/2005
12	TrabectedinIBA 01/2021 - 09/2006
11	Poly(ADP-ribose) Polymerase InhibitorsIBA 07/2022 - 09/2015
11	1-dodecylpyridoxal (PLD)IBA 11/2021 - 07/2010
11	Topotecan (Hycamtin)FDA LinkGeneric 10/2017 - 07/2005
10	VaccinesIBA 01/2022 - 08/2005
8	niraparibIBA 07/2022 - 12/2016
8	taxaneIBA 01/2019 - 10/2007
8	Proteins (Proteins, Gene)FDA Link 10/2017 - 08/2005
5	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2020 - 01/2016
5	trebananibIBA 01/2019 - 09/2013
4	rucaparibIBA 12/2022 - 01/2020
4	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2019
4	pembrolizumabIBA 01/2022 - 01/2021
4	olaparibIBA 10/2020 - 09/2015
4	Angiogenesis InhibitorsIBA 10/2020 - 12/2009
4	DNA (Deoxyribonucleic Acid)IBA 09/2015 - 09/2003
4	Papillomavirus Vaccines (HPV Vaccines)IBA 05/2008 - 08/2005
3	balstilimabIBA 01/2022 - 09/2021
3	tisotumab vedotinIBA 01/2022 - 01/2021
3	FANG vaccineIBA 12/2021 - 12/2020
3	avelumabIBA 01/2021 - 09/2018
3	Biosimilar PharmaceuticalsIBA 01/2017 - 06/2015
3	Ifosfamide FDA LinkGeneric 11/2016 - 02/2007
3	Docetaxel (Taxotere)FDA Link 02/2015 - 03/2011
3	pazopanib FDA Link 10/2014 - 08/2010
3	AgarIBA 08/2012 - 11/2002
3	Fluorouracil (Carac)FDA LinkGeneric 12/2006 - 03/2005
2	LigandsIBA 10/2022 - 01/2020
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 10/2020
2	lenvatinibIBA 01/2022 - 01/2021
2	NivolumabIBA 01/2022 - 12/2021
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2022
2	Monoclonal AntibodiesIBA 12/2021 - 12/2011
2	CytokinesIBA 02/2021 - 09/2019
2	fosbretabulin (combretastatin A4)IBA 10/2020 - 01/2016
2	TubulinIBA 10/2020 - 01/2017
2	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 12/2019 - 12/2016
2	Adenosine Diphosphate (ADP)IBA 12/2019 - 12/2016
2	Angiopoietin-1IBA 01/2019 - 10/2016
2	Estrogen ReceptorsIBA 01/2018 - 09/2015
2	AntigensIBA 01/2018 - 01/2017
2	AnthracyclinesIBA 11/2016 - 01/2012
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2012 - 03/2006
2	Lapatinib (GW572016)FDA Link 12/2011 - 08/2010
2	insulin receptor-related receptor (IRR)IBA 12/2010 - 10/2005

Therapy/Procedure

86	Therapeutics 01/2022 - 12/2002
70	Drug Therapy (Chemotherapy) 12/2022 - 11/2002
14	Radiotherapy 11/2021 - 03/2002
11	Immunotherapy 01/2022 - 11/2014
6	Hysterectomy 01/2021 - 09/2003
4	Lymph Node Excision (Lymph Node Dissection) 11/2021 - 09/2003
4	Brachytherapy 11/2014 - 03/2002
4	Combination Drug Therapy (Combination Chemotherapy) 02/2014 - 08/2004
3	Chemoradiotherapy 01/2020 - 11/2005
2	Neoadjuvant Therapy 01/2021 - 01/2016
2	Laparotomy 02/2019 - 11/2008